Series B · Biotech · Zurich, Switzerland · Founded 2017
Synthetic Virus-Like Particle (SVLP) platform for fully synthetic nanoparticle vaccines against infectious diseases like pneumococcal disease. Clinical-stage with V-212 in Phase 1 trials showing positive data as of January 2026. Raised $15M financing in November 2025 and CHF 7.5M Series B in 2020.
No open roles listed right now.